Suven Life Sciences to Present Global Phase-3 Masupirdine Study Updates at AAIC 2026 in London
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on CNS disorders, is set to participate in the Alzheimer's Association International Conference (AAIC) 2026. The conference, designated as A Global Forum to Advance Dementia Science, will be held in London, United Kingdom, from July 12 to 15, 2026.The company has announced it will present five scientific posters detailing its ongoing research and clinical programs across the neuroscience pipeline. Highlights of the presentations include updates on Masupirdine, a pure 5-HT6R Antagonist, which is in a global Phase-3 Clinical Trial Program targeting agitation associated with Alzheimer's Dementia. Suven will also showcase the clinical development program for Usmarapride, a selective 5-HT4R partial agonist intended for cognitive disorders.
The AAIC is recognized as the largest international conference dedicated to advancing dementia science and clinical practice. During the event, Suven Life Sciences will provide insights into the demographic and clinical characteristics of patients enrolled in its Masupirdine study, demonstrating progress in managing agitation related to Alzheimer's disease dementia. The company also plans to showcase broader non-clinical and clinical research advances across its pipeline while engaging with key opinion leaders and strategic partners.
The five presentations scheduled for AAIC 2026 cover various stages of Suven’s CNS portfolio.
| Presentation Topic | Date/Day | Focus Area |
|---|---|---|
| Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SUVN-I6107 (M1 PAM) in Healthy Human Subjects | July 12th (Sunday) | Neuroscience |
| SUVN-L1101142: A Muscarinic 4 Positive Allosteric Modulator for AD and Schizophrenia | July 13th (Monday) | Alzheimer's Disease/Schizophrenia |
| Masupirdine: Updates from the Phase-3 Clinical Trial Program Targeting Agitation in Alzheimer's Dementia | July 15th (Wednesday) | Alzheimer's Dementia |
| Usmarapride Update: Clinical Development Program for Cognitive Disorders | July 15th (Wednesday) | Cognitive Disorders |
| Efficacy and Safety of SUVN-N9503012, a Selective 5-HT1A Partial Agonist for Neurodegenerative Disorders | July 15th (Wednesday) | Neurodegenerative Disorders |
Conference attendees are invited to visit Suven's Exhibit Booth #117. The company's scientific and business development teams will be present throughout the meeting to discuss its clinical-stage neuroscience pipeline, ongoing programs, future strategy, and potential collaboration opportunities with pharmaceutical and biotechnology companies.
About Suven Life Sciences
Suven Life Sciences Limited is focused on discovery and clinical development of innovative medicines addressing unmet medical needs in CNS disorders. The company maintains a portfolio of advanced stage clinical candidates for conditions including Alzheimer's disease (AD), Major depressive disorders (MDD), Parkinson’s disease (PD), Schizophrenia, Sleep disorders, Pain disorders, and Gastrointestinal disorders.Key assets include:
- Masupirdine (SUVN-502): A Global Phase-3 study is ongoing for the treatment of agitation in patients with dementia of the Alzheimer's type.
- Samelisant (SUVN-G3031): This asset is involved in a Phase-2 study for EDS, and planning is underway for a pivotal Phase-3 study for EDS and a Phase-2 study for Cataplexy.
- Ropanicant (SUVN-911): The company has completed an open-label Phase-2a study and a double blind randomized placebo controlled Phase-2b proof of concept study for MDD.
- Usmarapride (SUVN-D4010): A Phase-2 study is currently in planning for cognitive disorders.
- SUVN-I6107: This asset has completed a Phase-1 study for cognitive disorders.
In addition to these clinical assets, Suven maintains seven projects in its research pipeline across multiple indications. The company holds all intellectual property rights for its assets in major markets.
SUVEN Stock Price Movement
As of 12:30 PM, shares of Suven Life Sciences Limited are shedding slightly in live trading, dipping by 0.30% to currently trade at ₹345.70. The equity has experienced notable volatility and previously reached a remarkable 52-week high of ₹370.8, with over 2.71 million shares traded so far today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: